KalVista Pharmaceuticals (KALV) News Today → Moonshot Coins for the Current Crypto Run (From Crypto 101 Media) (Ad) Free KALV Stock Alerts $12.04 +0.36 (+3.08%) (As of 06/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 10 at 7:50 PM | marketbeat.comBenjamin L. Palleiko Sells 7,465 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) StockKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 7,465 shares of the stock in a transaction on Friday, June 7th. The shares were sold at an average price of $11.53, for a total transaction of $86,071.45. Following the completion of the sale, the chief executive officer now owns 224,547 shares of the company's stock, valued at approximately $2,589,026.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.June 6, 2024 | businesswire.comKalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024June 6, 2024 | businesswire.comKalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024June 5, 2024 | marketbeat.comAffinity Asset Advisors LLC Sells 152,323 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Affinity Asset Advisors LLC cut its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 54.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 125,969 shares of the specialJune 4, 2024 | businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 31, 2024 | businesswire.comKalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary AngioedemaMay 24, 2024 | businesswire.comKalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024May 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), LAVA Therapeutics (LVTX) and Crinetics Pharmaceuticals (CRNX)May 22, 2024 | insidertrades.comInsider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells 8,088 Shares of StockMay 22, 2024 | insidertrades.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 21,959 SharesMay 21, 2024 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Edward P. Feener Sells 8,088 SharesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Edward P. Feener sold 8,088 shares of the company's stock in a transaction on Monday, May 20th. The stock was sold at an average price of $11.76, for a total value of $95,114.88. Following the sale, the insider now owns 72,858 shares of the company's stock, valued at approximately $856,810.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.May 21, 2024 | finance.yahoo.comBreakeven On The Horizon For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)May 21, 2024 | businesswire.comKalVista Pharmaceuticals to Present at Upcoming Investor ConferencesMay 12, 2024 | morningstar.comKalVista Pharmaceuticals Inc KALVMay 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Masimo (MASI)May 3, 2024 | marketbeat.comHC Wainwright Cuts KalVista Pharmaceuticals (NASDAQ:KALV) Price Target to $20.00HC Wainwright reduced their target price on shares of KalVista Pharmaceuticals from $24.00 to $20.00 and set a "buy" rating for the company in a research note on Friday.May 1, 2024 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 6.8%KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 6.8%May 1, 2024 | marketbeat.comKalVista Pharmaceuticals' (KALV) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $35.00 price objective on shares of KalVista Pharmaceuticals in a report on Wednesday.May 1, 2024 | finance.yahoo.comKalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal YearApril 22, 2024 | businesswire.comKalVista Pharmaceuticals Appoints William C. Fairey to Board of DirectorsApril 18, 2024 | marketbeat.comLeerink Partnrs Weighs in on KalVista Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:KALV)KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of KalVista Pharmaceuticals in a research report issued on Tuesday, April 16th. Leerink Partnrs analyst J. Schwartz expects that the specialty pharmaceutical compApril 17, 2024 | fool.comKalVista Pharmaceuticals (NASDAQ: KALV)April 15, 2024 | marketbeat.comVanguard Group Inc. Acquires 151,808 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Vanguard Group Inc. increased its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 9.6% in the third quarter, according to its most recent filing with the SEC. The fund owned 1,732,489 shares of the specialty pharmaceutical company's stock after acquiring an additApril 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rallybio (RLYB), Phathom Pharmaceuticals (PHAT) and Amylyx Pharmaceuticals Inc (AMLX)April 11, 2024 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $35.00 price target on shares of KalVista Pharmaceuticals in a report on Thursday.April 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)April 3, 2024 | businesswire.comKalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare ConferenceApril 2, 2024 | businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 28, 2024 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Sees Unusually-High Trading VolumeKalVista Pharmaceuticals (NASDAQ:KALV) Sees Strong Trading VolumeMarch 18, 2024 | finance.yahoo.comKalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference AmericasMarch 18, 2024 | marketbeat.comResearch Analysts Offer Predictions for KalVista Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:KALV)KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a report released on Wednesday, March 13th. Cantor Fitzgerald analyst C. Duncan now anticipates that theMarch 16, 2024 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Up 50.8% in FebruaryKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) saw a large growth in short interest in February. As of February 29th, there was short interest totalling 4,510,000 shares, a growth of 50.8% from the February 14th total of 2,990,000 shares. Approximately 18.6% of the company's shares are sold short. Based on an average daily trading volume, of 762,300 shares, the days-to-cover ratio is currently 5.9 days.March 15, 2024 | marketbeat.comLeerink Partnrs Comments on KalVista Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:KALV)KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Leerink Partnrs decreased their FY2024 earnings per share (EPS) estimates for shares of KalVista Pharmaceuticals in a research note issued to investors on Tuesday, March 12th. Leerink Partnrs analyst J. Schwartz now forecasts that the sMarch 14, 2024 | marketbeat.comFY2024 EPS Estimates for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Lifted by HC WainwrightKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Analysts at HC Wainwright upped their FY2024 earnings estimates for shares of KalVista Pharmaceuticals in a research note issued to investors on Tuesday, March 12th. HC Wainwright analyst A. Fein now forecasts that the specialty pharmacMarch 13, 2024 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Forecasted to Earn Q1 2025 Earnings of ($0.57) Per ShareKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for KalVista Pharmaceuticals in a note issued to investors on Tuesday, March 12th. HC Wainwright analyst A. Fein expects that the specialty pharmaceutical company wMarch 12, 2024 | markets.businessinsider.comBuy Rating on KalVista Pharmaceuticals Backed by Sebetralstat’s Breakthrough in HAE TreatmentMarch 12, 2024 | finance.yahoo.comKalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for SebetralstatMarch 11, 2024 | markets.businessinsider.comBuy Rating Reinforced by Strategic CEO Appointment and Promising Drug Development at KalVista PharmaceuticalsMarch 11, 2024 | businesswire.comKalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational UpdateMarch 8, 2024 | finanznachrichten.deKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference AmericasMarch 8, 2024 | businesswire.comKalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference AmericasMarch 7, 2024 | marketwatch.comKalVista Pharmaceuticals Stock Falls After CEO ResignsMarch 7, 2024 | markets.businessinsider.comKalVista Stock Drops After Announcement Of Resignation Of CEO Andrew CrockettMarch 7, 2024 | marketwatch.comKalVista Pharmaceuticals Names Benjamin Palleiko Chief Executive, DirectorMarch 7, 2024 | businesswire.comKalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive OfficerMarch 6, 2024 | businesswire.comKalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma ConferenceMarch 4, 2024 | businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 4, 2024 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Sees Large Growth in Short InterestKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 2,990,000 shares, an increase of 21.1% from the January 31st total of 2,470,000 shares. Currently, 12.4% of the company's shares are sold short. Based on an average daily volume of 686,700 shares, the days-to-cover ratio is currently 4.4 days.March 1, 2024 | marketbeat.comMPM Bioimpact LLC Has $5.57 Million Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)MPM Bioimpact LLC trimmed its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 24.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 577,958 shares of the spFebruary 29, 2024 | marketbeat.comAnalysts Set Expectations for KalVista Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:KALV)KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of KalVista Pharmaceuticals in a research report issued on Monday, February 26th. Cantor Fitzgerald analyst C. Duncan now anticipates that the specialty ph Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address New trading system called MSFT, NVDA & MSFT (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today. Just follow this link here! KALV Media Mentions By Week KALV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KALV News Sentiment▼0.470.75▲Average Medical News Sentiment KALV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KALV Articles This Week▼42▲KALV Articles Average Week Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ABUS News ALIM News BCRX News ZLAB News GLPG News KROS News PTGX News NAMS News GPCR News EVO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KALV) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored